Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Gross Margin (2016 - 2025)

Historic Gross Margin for Niagen Bioscience (NAGE) over the last 17 years, with Q3 2025 value amounting to 64.52%.

  • Niagen Bioscience's Gross Margin rose 10300.0% to 64.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 63.89%, marking a year-over-year increase of 24500.0%. This contributed to the annual value of 61.84% for FY2024, which is 10700.0% up from last year.
  • Latest data reveals that Niagen Bioscience reported Gross Margin of 64.52% as of Q3 2025, which was up 10300.0% from 65.0% recorded in Q2 2025.
  • Niagen Bioscience's 5-year Gross Margin high stood at 65.0% for Q2 2025, and its period low was 57.23% during Q4 2022.
  • In the last 5 years, Niagen Bioscience's Gross Margin had a median value of 61.08% in 2021 and averaged 61.44%.
  • Its Gross Margin has fluctuated over the past 5 years, first soared by 49500bps in 2021, then crashed by -39700bps in 2022.
  • Over the past 5 years, Niagen Bioscience's Gross Margin (Quarter) stood at 61.2% in 2021, then decreased by -6bps to 57.23% in 2022, then increased by 7bps to 61.04% in 2023, then rose by 2bps to 62.48% in 2024, then increased by 3bps to 64.52% in 2025.
  • Its Gross Margin stands at 64.52% for Q3 2025, versus 65.0% for Q2 2025 and 63.42% for Q1 2025.